Euronext Paris · Healthcare
Invest in Predilife stock from India
Indian and foreign residents can buy Predilife (ALPRE) shares directly through Paasa.
By Paasa · Updated
Predilife at a glance
- Price
- €1.01-€0.02 (1.46%)
- Market cap
- €3.98M
- Day range
- €0.90 – €1.01
- P/E
- -1.00
- Dividend yield
- None
- Volume
- 507.00
- 1 month
- -9.82%
- 6 months
- -67.31%
- YTD
- -66.45%
- 1 year
- -68.73%
- 5 years
- -84.46%
Predilife statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | €1.1M | €618.1K | €317.8K | €288.6K | €142.1K |
| Gross profit | €1.1M | €604.2K | €303.1K | €244.4K | −€2.0M |
| Operating income | −€2.9M | −€4.0M | −€3.8M | −€3.5M | −€3.5M |
| Net income | −€3.5M | €198.6M | −€4.2M | −€3.7M | −€3.4M |
| Earnings per share | −€1.00 | €53.69 | −€1.14 | −€1.00 | −€0.94 |
| EBITDA | −€2.7M | −€4.0M | −€3.8M | −€3.5M | −€3.5M |
| Total assets | €1.8M | €2.4M | €8.8M | €4.7M | €4.0M |
| Total debt | €5.5M | €4.9M | €7.2M | €7.3M | €5.1M |
| Cash and short-term investments | €556.9K | €1.1M | €3.4M | €3.8M | €2.9M |
| Shareholders' equity | −€6.9M | −€4.3M | €513.5K | −€5.2M | −€1.6M |
| Operating cash flow | −€2.6M | −€3.7M | −€4.2M | −€3.1M | −€3.8M |
| Free cash flow | −€2.6M | −€3.7M | −€4.3M | −€3.1M | −€3.8M |
| Capital expenditure | −€2.0K | −€5.4K | −€42.4K | −€27.0K | −€3.4K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in EUR; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Mauna Kea Technologies | ALMKT.PA | €0.14 | €27.34M |
| Valbiotis | ALVAL.PA | €0.69 | €24.49M |
| Biosynex | ALBIO.PA | €0.87 | €16.11M |
| Euromedis Groupe | ALEMG.PA | €5.10 | €14.57M |
| Aelis Farma | AELIS.PA | €0.90 | €12.27M |
| Intrasense | ALINS.PA | €0.19 | €9.93M |
| TME Pharma | ALTME.PA | €0.10 | €9.81M |
| AMA | ALAMA.PA | €0.17 | €8.94M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Predilife from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to EUR when you buy.
Step 3
Search ALPRE and buy
Find Predilife by name or by its ticker, ALPRE, and place your order.
Why invest in Predilife from India
What Predilife does
Founded in 2004 and headquartered in Villejuif, France, Predilife S.A. specializes in devising and commercializing sophisticated medical technologies and analytical models. The company's core offerings include preventative healthcare solutions and comprehensive breast screening tests. Predilife operates in the Medical - Diagnostics & Research industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Predilife stock from India?
Yes. Indian residents and NRIs can buy Predilife (ALPRE) shares directly through Paasa. Predilife is listed on Euronext Paris, in the Medical - Diagnostics & Research industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Predilife shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the EUR/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.